{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:35Z","timestamp":1787841335090,"version":"build-2784847793"},"reference-count":81,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Research, Innovation, and Digitization, CCCDI-UEFISCDI","award":["PN-IV-P7-7.1-PED-2024-0307"],"award-info":[{"award-number":["PN-IV-P7-7.1-PED-2024-0307"]}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Cells"],"abstract":"<jats:p>Aggressive thyroid carcinomas\u2014anaplastic (ATC) and poorly differentiated (PDTC)\u2014are rare but highly lethal malignant entities. Their immunophenotypical characterization is still incomplete, and no standardized diagnostic algorithms have been used. Our study retrospectively analyzes 40 thyroidectomy cases as follows: 12 ATC and 28 PDTC from 2014 to 2024 by evaluating clinical data, histopathological aspects, molecular analysis for presence of BRAFV600E and TERTC228\/250T mutations, as well as immunohistochemical expression of BRAFV600E, total BRAF, K-RAS, TERT, PAX-8, TTF-1, P53, and Ki-67. BRAFV600E was present in 70% of cases, with higher prevalence in ATC. Total BRAF correlated positively with K-RAS and TERT and negatively with BRAFV600E. TERT abnormal expression was highly prevalent in over 90% of cases, while loss of TTF-1 and PAX-8 is associated with anaplastic transformation. Ki-67 proliferative index had significantly higher values in ATC, thus supporting its role as a marker for aggressiveness. On univariate analysis, higher Ki-67 indices and lymph node invasion are independent predictor factors for the presence of metastases. However, on multivariate analysis, they both lose significance. Upon multivariate analysis, loss of TTF-1 and tumor necrosis were significant predictors for anaplastic histotype. Specific BRAFV600E immunohistochemistry may be a good screening tool for the BRAFV600E mutation. Molecularly, there is a relatively frequent association of the BRAFV600E mutation and TERTC228, mainly in the PDTC subgroup. Patterns of marker expression suggest that BRAF or RAF activation with subsequent loss of TTF-1 or PAX-8, TERT upregulation, and TP53 alteration are frequent occurrences in aggressive thyroid carcinomas. The association between TTF-1 loss and anaplastic transformation, presence of necrosis alongside BRAFV600E, underlines their diagnostic potential in subclassifying aggressive thyroid carcinomas.<\/jats:p>","DOI":"10.3390\/cells14191554","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T13:33:41Z","timestamp":1759757621000},"page":"1554","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunophenotypic Panel for Comprehensive Characterization of Aggressive Thyroid Carcinomas"],"prefix":"10.3390","volume":"14","author":[{"given":"Mihail","family":"Ceausu","sequence":"first","affiliation":[{"name":"Department of Pathology, \u201cC.I. Parhon\u201d National Institute of Endocrinology, 011863 Bucharest, Romania"},{"name":"Department of Pathology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6943-8444","authenticated-orcid":false,"given":"Mihai Alin","family":"Publik","sequence":"additional","affiliation":[{"name":"Department of Pathology, \u201cC.I. Parhon\u201d National Institute of Endocrinology, 011863 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Terzea","sequence":"additional","affiliation":[{"name":"Department of Pathology, \u201cC.I. Parhon\u201d National Institute of Endocrinology, 011863 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Adina","family":"Cristea","sequence":"additional","affiliation":[{"name":"Department of Pathology, \u201cC.I. Parhon\u201d National Institute of Endocrinology, 011863 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dumitru","family":"Ioachim","sequence":"additional","affiliation":[{"name":"Department of Pathology, \u201cC.I. Parhon\u201d National Institute of Endocrinology, 011863 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Manda","sequence":"additional","affiliation":[{"name":"Department of Research, \u201cC.I. Parhon\u201d National Institute of Endocrinology, 011863 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4886-2174","authenticated-orcid":false,"given":"Sorina","family":"Schipor","sequence":"additional","affiliation":[{"name":"Department of Research, \u201cC.I. Parhon\u201d National Institute of Endocrinology, 011863 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"ref_1","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2024). Global Cancer Observatory: Cancer Today, International Agency for Research on Cancer."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Gao, M.Z., Omer, T.M., Miller, K.M., Simpson, M.C., Bukatko, A.R., Gedion, K., Boakye, E.A., Kost, K.M., Dickinson, J.A., and Varvares, M.A. (2025). Thyroid Cancer Incidence and Trends in United States and Canadian Pediatric, Adolescent, and Young Adults. Cancers, 17.","DOI":"10.3390\/cancers17091429"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e220146","DOI":"10.1530\/ETJ-22-0146","article-title":"2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma","volume":"11","author":"Lebbink","year":"2022","journal-title":"Eur. Thyroid. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.32125","article-title":"Trends in pediatric thyroid cancer incidence in the United States, 1998\u20132013","volume":"125","author":"Bernier","year":"2019","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1158\/1055-9965.EPI-21-1440","article-title":"Epidemiology of Thyroid Cancer","volume":"31","author":"Kitahara","year":"2022","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"965212","DOI":"10.1155\/2013\/965212","article-title":"Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors","volume":"2013","author":"Pellegriti","year":"2013","journal-title":"J. Cancer Epidemiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/sj.bjc.6603578","article-title":"Poorly differentiated and anaplastic thyroid carcinomas: Chromosomal and oligo-array profile of five new cell lines","volume":"96","author":"Rodrigues","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrendo.2017.76","article-title":"Anaplastic thyroid carcinoma: From clinicopathology to genetics and advanced therapies","volume":"13","author":"Molinaro","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"122110","DOI":"10.1016\/j.lfs.2023.122110","article-title":"Advances and challenges in thyroid cancer: The interplay of genetic modulators, targeted therapies, and AI-driven approaches","volume":"332","author":"Bhattacharya","year":"2023","journal-title":"Life Sci."},{"key":"ref_10","unstructured":"WHO Classification of Tumours Editorial Board (2022). Endocrine and Neuroendocrine Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Schipor, S., Publik, M.A., Manda, D., and Ceausu, M. (2025). Aggressive Thyroid Carcinomas Clinical and Molecular Features: A Systematic Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26125535"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1634\/theoncologist.2014-0182","article-title":"Novel Approaches in Anaplastic Thyroid Cancer Therapy","volume":"19","author":"Hsu","year":"2014","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Al-Ibraheem, A., Al-Rasheed, U., Mashhadani, N., Abdlkadir, A.S., Al-Adhami, D.A., Ruzzeh, S., Istatieh, F., Mansour, A., Hamdan, B., and Kheetan, R. (2023). Long-Term Survival Analysis and Prognostic Factors of Arabic Patients with Differentiated Thyroid Carcinoma: A 20-Year Observational Study at the King Hussein Cancer Center (KHCC) Involving 528 Patients. Cancers, 15.","DOI":"10.3390\/cancers15164102"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Patel, J., Klopper, J., and Cottrill, E.E. (2023). Molecular diagnostics in the evaluation of thyroid nodules: Current use and prospective opportunities. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1101410"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Guo, Y., Zhong, Q., Xie, L., Wang, X., Guo, L., Zhuang, S., Jia, C., Wu, L., Peng, J., and Pang, F. (2025). Development of a new TNM staging system for poorly differentiated thyroid carcinoma: A multicenter cohort study. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1586542"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.path.2022.09.006","article-title":"No Longer Well-Differentiated: Diagnostic Criteria and Clinical Importance of Poorly Differentiated\/High-Grade Thyroid Carcinoma","volume":"16","author":"Cracolici","year":"2023","journal-title":"Surg. Pathol. Clin."},{"key":"ref_17","unstructured":"(2025, August 12). BlueBooksOnline. Available online: https:\/\/tumourclassification.iarc.who.int\/chaptercontent\/53\/47."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.amjsurg.2021.11.038","article-title":"Vascular invasion predicts advanced tumor characteristics in papillary thyroid carcinoma","volume":"223","author":"Reilly","year":"2022","journal-title":"Am. J. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bertol, B.C., Massaro, J.D., Debortoli, G., Santos, A.L.P., de Ara\u00fajo, J.N.G., Giorgenon, T.M.V., e Silva, M.C., de Figueiredo-Feitosa, N.L., Collares, C.V.A., and de Freitas, L.C.C. (2023). BRAF, TERT and HLA-G Status in the Papillary Thyroid Carcinoma: A Clinicopathological Association Study. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512459"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1530\/EC-18-0386","article-title":"Not the same thing: Metastatic PTCs have a different background than ATCs","volume":"7","author":"Torricelli","year":"2018","journal-title":"Endocr. Connect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/modpathol.2010.117","article-title":"Poorly differentiated carcinoma of the thyroid: Validation of the Turin proposal and analysis of IMP3 expression","volume":"23","author":"Asioli","year":"2010","journal-title":"Mod. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/thy.2020.0086","article-title":"Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases","volume":"30","author":"Xu","year":"2020","journal-title":"Thyroid"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00000658-200003000-00005","article-title":"Insular and anaplastic carcinoma of the thyroid: A 45-year comparative study at a single institution and a review of the significance of p53 and p21","volume":"231","author":"Lam","year":"2000","journal-title":"Ann. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12022-016-9445-4","article-title":"Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma","volume":"27","author":"Xu","year":"2016","journal-title":"Endocr. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrc1836","article-title":"Pathogenetic mechanisms in thyroid follicular-cell neoplasia","volume":"6","author":"Kondo","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13044-020-00091-w","article-title":"Recent advances in the management of anaplastic thyroid cancer","volume":"13","author":"Trevisan","year":"2020","journal-title":"Thyroid. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4132\/jptm.2024.11.08","article-title":"Low Ki-67 labeling index is a clinically useful predictive factor for recurrence-free survival in patients with papillary thyroid carcinoma","volume":"59","author":"Masui","year":"2025","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3892\/mmr.2014.2914","article-title":"Ki67 is a promising molecular target in the diagnosis of cancer (Review)","volume":"11","author":"Li","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref_30","unstructured":"Seethala, R.R., Asa, S.L., Bullock, M.J., Carty, S.E., Hodak, S.P., McHugh, J.B., Nikiforov, Y.E., Pettus, J., Richardson, M.S., and Shah, J. (2017). Protocol for the Examination of Specimens from Patients with Carcinomas of the Thyroid Gland, American College of Parthologists."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/j.semdp.2014.12.012","article-title":"Undifferentiated (anaplastic) thyroid carcinoma: Practical immunohistochemistry and cytologic look-alikes","volume":"32","author":"Talbott","year":"2015","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Crescenzi, A., and Baloch, Z. (2023). Immunohistochemistry in the pathologic diagnosis and management of thyroid neoplasms. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1198099"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00292-019-0600-9","article-title":"Gering differenzierte Schilddr\u00fcsenkarzinome: Eine unterdiagnostizierte Entit\u00e4t","volume":"41","author":"Dettmer","year":"2020","journal-title":"Der Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Walczyk, A., Kopczy\u0144ski, J., G\u0105sior-Perczak, D., Pa\u0142yga, I., Kowalik, A., Chrapek, M., Hejnold, M., G\u00f3\u017ad\u017a, S., and Kowalska, A. (2020). Histopathology and immunohistochemistry as prognostic factors for poorly differentiated thyroid cancer in a series of Polish patients. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229264"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.humpath.2011.02.004","article-title":"PAX8 immunostaining of anaplastic thyroid carcinoma: A reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck","volume":"42","author":"Bishop","year":"2011","journal-title":"Hum. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"(2025, July 24). Induction of TTF-1 or PAX-8 Expression on Proliferation and Tumorigenicity in Thyroid Carcinomas. Available online: https:\/\/www.spandidos-publications.com\/ijo\/49\/3\/1248.","DOI":"10.3892\/ijo.2016.3617"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lacka, K., Maciejewski, A., Tyburski, P., Manuszewska-Jopek, E., Majewski, P., and Wi\u0119ckowska, B. (2025). Rationale for Testing TP53 Mutations in Thyroid Cancer\u2014Original Data and Meta-Analysis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26031035"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.31557\/APJCP.2022.23.11.3617","article-title":"Relationship between the Expression of BRAF V600E and Ki-67 with the Recurrence of Well-Differentiated Thyroid Cancer","volume":"23","author":"Harahap","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/PAS.0b013e3180309e6a","article-title":"Poorly differentiated thyroid carcinoma: The Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach","volume":"31","author":"Volante","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"74897","DOI":"10.18632\/oncotarget.20451","article-title":"Immunohistochemistry cannot replace DNA analysis for evaluation of BRAFV600E mutations in papillary thyroid carcinoma","volume":"8","author":"Szymonek","year":"2017","journal-title":"Oncotarget"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/his.15185","article-title":"Exploring p53 protein expression and its link to TP53 mutation in myelodysplasia-related malignancies\u2014Interpretive challenges and potential field of applications","volume":"85","author":"Bedekovics","year":"2024","journal-title":"Histopathology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4132\/jptm.2020.06.01","article-title":"Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer","volume":"54","author":"Hwang","year":"2020","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0039-6109(16)46631-4","article-title":"Thyroid Growth Factors, Signal Transduction Pathways, and Oncogenes","volume":"75","author":"Ouh","year":"1995","journal-title":"Surg. Clin. N. Am."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Smith, T.J. (2021). Insulin-Like Growth Factor Pathway and the Thyroid. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.653627"},{"key":"ref_45","unstructured":"(2025, July 24). ERK\/MAPK Signalling Pathway and Tumorigenesis (Review). Available online: https:\/\/www.spandidos-publications.com\/10.3892\/etm.2020.8454."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.28864","article-title":"The MAPK pathway across different malignancies: A new perspective","volume":"120","author":"Burotto","year":"2014","journal-title":"Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3109\/10799893.2015.1030412","article-title":"Signaling pathway of MAPK\/ERK in cell proliferation, differentiation, migration, senescence and apoptosis","volume":"35","author":"Sun","year":"2015","journal-title":"J. Recept. Signal Transduct."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Maik-Rachline, G., Hacohen-Lev-Ran, A., and Seger, R. (2019). Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051194"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/his.13942","article-title":"Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing","volume":"75","author":"Duan","year":"2019","journal-title":"Histopathology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s12020-024-03738-y","article-title":"Genetic landscape of 482 thyroid carcinomas: Analysis with the national datacenter for cancer genomic medicine in Japan","volume":"85","author":"Yamazaki","year":"2024","journal-title":"Endocrine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1002\/cjp2.356","article-title":"Anaplastic and poorly differentiated thyroid carcinomas: Genetic evidence of high-grade transformation from differentiated thyroid carcinoma","volume":"10","author":"Gu","year":"2024","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Chai, Y.J., Yi, J.W., Jee, H.-G., A Kim, Y., Kim, J.H., Xing, M., and Lee, K.E. (2016). Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159235"},{"key":"ref_53","first-page":"e64872","article-title":"Deciphering the Role of BRAFV600E Immunohistochemistry in Breast Lesions: A Comprehensive Review","volume":"16","author":"Khan","year":"2024","journal-title":"Cureus"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Tsutsumi, Y. (2021). Pitfalls and Caveats in Applying Chromogenic Immunostaining to Histopathological Diagnosis. Cells, 10.","DOI":"10.20944\/preprints202104.0750.v1"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s12105-020-01166-8","article-title":"Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis","volume":"14","author":"Parker","year":"2020","journal-title":"Head Neck Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/PAT.0000000000000119","article-title":"Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: Impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma","volume":"46","author":"Dvorak","year":"2014","journal-title":"Pathology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.humpath.2007.04.014","article-title":"Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas","volume":"38","author":"Kondo","year":"2007","journal-title":"Hum. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/mutage\/get066","article-title":"Impact of molecular alterations of BRAF in the pathogenesis of thyroid cancer","volume":"29","author":"Khan","year":"2014","journal-title":"Mutagenesis"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"099","DOI":"10.1385\/EP:16:2:099","article-title":"BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization","volume":"16","author":"Ciampi","year":"2005","journal-title":"Endocr. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1677\/erc.1.01119","article-title":"The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+\/I\u2212 targeting to the membrane","volume":"13","author":"Nistal","year":"2006","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1677\/ERC-07-0130","article-title":"BRAFV600E mutation, but not RET\/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer","volume":"15","author":"Romei","year":"2008","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12022-024-09836-x","article-title":"Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management","volume":"35","author":"Mete","year":"2024","journal-title":"Endocr. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1038\/sj.onc.1203723","article-title":"The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway","volume":"19","author":"Shirokawa","year":"2000","journal-title":"Oncogene"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1200\/JCO.2003.10.130","article-title":"ras Mutations Are Associated With Aggressive Tumor Phenotypes and Poor Prognosis in Thyroid Cancer","volume":"21","author":"Zhao","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3892\/ol.2010.219","article-title":"Utility of BRAF protein overexpression in predicting the metastasis potential of papillary thyroid carcinoma","volume":"2","author":"Feng","year":"2011","journal-title":"Oncol. Lett."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1038\/s41388-019-0872-9","article-title":"Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: Old actors and new players","volume":"38","author":"Yuan","year":"2019","journal-title":"Oncogene"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1158\/0008-5472.CAN-11-3605","article-title":"Activation of Ras\/PI3K\/ERK Pathway Induces c-Myc Stabilization to Upregulate Argininosuccinate Synthetase, Leading to Arginine Deiminase Resistance in Melanoma Cells","volume":"72","author":"Tsai","year":"2012","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/cncy.21474","article-title":"Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics","volume":"122","author":"Radkay","year":"2014","journal-title":"Cancer Cytopathol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Tayubi, I.A., and Madar, I.H. (2023). Identification of potential inhibitor targeting KRAS mutation in Papillary Thyroid Carcinoma through molecular docking and dynamic simulation analysis. Comput. Biol. Med., 152.","DOI":"10.1016\/j.compbiomed.2022.106377"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Mannino, D., Basilotta, R., De Luca, F., Casili, G., Esposito, E., and Paterniti, I. (2025). KRAS\u2013SOS-1 Inhibition as New Pharmacological Target to Counteract Anaplastic Thyroid Carcinoma (ATC). Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26062579"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"13144","DOI":"10.1073\/pnas.240336397","article-title":"Pax8 has a key role in thyroid cell differentiation","volume":"97","author":"Zannini","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"250116","DOI":"10.1530\/EC-25-0116","article-title":"BRAFV600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression","volume":"14","author":"Nhung","year":"2025","journal-title":"Endocr. Connect."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Rusinek, D., Pfeifer, A., Krajewska, J., Oczko-Wojciechowska, M., Handkiewicz-Junak, D., Pawlaczek, A., Zebracka-Gala, J., Kowalska, M., Cyplinska, R., and Zembala-Nozynska, E. (2018). Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092647"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"eadg7125","DOI":"10.1126\/sciadv.adg7125","article-title":"TERT accelerates BRAF mutant\u2013induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis","volume":"9","author":"Yu","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41467-018-03033-1","article-title":"Regulation of mutant TERT by BRAF V600E\/MAP kinase pathway through FOS\/GABP in human cancer","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1507\/endocrj.EJ20-0063","article-title":"BRAF and TERT promoter mutations: Clinical application in thyroid cancer","volume":"67","author":"Chung","year":"2020","journal-title":"Endocr. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.2147\/OTT.S135593","article-title":"The diagnostic and prognostic values of Ki-67\/MIB-1 expression in thyroid cancer: A meta-analysis with 6,051 cases","volume":"10","author":"Pan","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.3390\/curroncol31070300","article-title":"Ki-67 Labelling Index as a Predictor of Invasive Features in Thyroid Cancer: Retrospective Analysis and Implications","volume":"31","author":"Chowdhury","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1309\/AJCPOBI5CUZIBMO1","article-title":"VE1 Antibody Is Not Highly Specific for the BRAF V600E Mutation in Thyroid Cytology Categories With the Exception of Malignant Cases","volume":"143","author":"Lee","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"41453","DOI":"10.18632\/oncotarget.6162","article-title":"VE1 immunohistochemistry predicts BRAFV600E mutation status and clinical outcome in colorectal cancer","volume":"6","author":"Schafroth","year":"2015","journal-title":"Oncotarget"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/19\/1554\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:16:59Z","timestamp":1759825019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/19\/1554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":81,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cells14191554"],"URL":"https:\/\/doi.org\/10.3390\/cells14191554","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]}}}